OS Therapies (NYSE:OSTX) Now Covered by Maxim Group

Maxim Group started coverage on shares of OS Therapies (NYSE:OSTX) in a report published on Tuesday morning,Benzinga reports. The brokerage issued a buy rating and a $8.00 price objective on the stock.

Several other research analysts have also commented on the company. Brookline Capital Management upgraded OS Therapies to a “strong-buy” rating in a research report on Thursday, August 22nd. EF Hutton Acquisition Co. I upgraded OS Therapies to a “strong-buy” rating in a report on Tuesday, September 3rd.

OS Therapies Price Performance

NYSE:OSTX opened at $2.00 on Tuesday. OS Therapies has a fifty-two week low of $1.58 and a fifty-two week high of $4.90. The business’s 50 day moving average is $2.81.

Hedge Funds Weigh In On OS Therapies

An institutional investor recently bought a new position in OS Therapies stock. Virtu Financial LLC purchased a new position in OS Therapies Inc (NYSE:OSTX) in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 10,045 shares of the company’s stock, valued at approximately $28,000.

About OS Therapies

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers.